TRANSCEND NHL 001研究中lisocabtagene maraleucel治疗复发或难治性大B细胞淋巴瘤的两年随访
TRANSCEND NHL 001研究显示,lisocabtagene maraleucel(liso-cel)作为复发或难治性大B细胞淋巴瘤的三线或以后治疗具有显著疗效和可控的安全性。中位随访19.9个月,可评估患者(N=257)客观缓解率73%、完全缓解率53%,中位无进展生存期6.8个月、总生存期27.3个月,2年总生存率50.5%。90天治疗中出现期3-4级细胞因子释放综合征和神经事件发生率分别为2%和10%,最常见≥3级不良事件为中性粒细胞减少(治疗中出现期60%)和贫血(37%)。
要点
- liso-cel三线或以后治疗复发或难治性大B细胞淋巴瘤,客观缓解率73%、完全缓解率53%。
- 中位随访19.9个月,中位总生存期27.3个月,2年总生存率50.5%。
- 90天治疗中出现期3-4级细胞因子释放综合征2%、神经事件10%。
核心结论
- liso-cel在复发或难治性大B细胞淋巴瘤患者中显示持久缓解和可控的安全性,2年随访期间未出现新的安全性信号。
研究设计与样本
- TRANSCEND NHL 001研究,liso-cel治疗复发或难治性大B细胞淋巴瘤患者N=270,中位年龄63岁(范围18-86岁),中位既往系统治疗线数3(范围1-8),181例(67%)为化疗难治性。
- 主要终点为不良事件、剂量限制性毒性和独立评审委员会评估的客观缓解率;关键次要终点为完全缓解率、缓解持续时间、无进展生存期和总生存期。
- 2年随访后患者可入组另一项评估长期(≤15年)安全性和总生存期的研究。
主要发现
- 可评估患者(N=257)客观缓解率73%,完全缓解率53%。
- 中位缓解持续时间23.1个月(95%CI 8.6至未达到),中位无进展生存期6.8个月(95%CI 3.3-12.7),中位总生存期27.3个月(95%CI 16.2-45.6)。
- 估计2年缓解持续时间率49.5%,2年无进展生存率40.6%,2年总生存率50.5%。
- 90天治疗中出现期(N=270)3-4级细胞因子释放综合征发生率2%,3-4级神经事件发生率10%。
- 治疗中出现期与治疗后出现期最常见的≥3级不良事件分别为中性粒细胞减少(60%和7%)和贫血(37%和6%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lisocabtagene maraleucel (liso-cel) demonstrated significant efficacy with a manageable safety profile as third-line or later treatment for patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) in the TRANSCEND NHL 001 study. Primary end points were adverse events (AEs), dose-limiting toxicities, and objective response rate (ORR) per independent review committee. Key secondary end points were complete response (CR) rate, duration of response (DOR), progression-free survival (PFS), and overall survival (OS). After 2-year follow-up, patients could enroll in a separate study assessing long-term (≤15 years) safety and OS. Liso-cel-treated patients (N = 270) had a median age of 63 years (range, 18-86 years) and a median of 3 prior lines (range, 1-8) of systemic therapy, and 181 of them (67%) had chemotherapy-refractory LBCL. Median follow-up was 19.9 months. In efficacy-evaluable patients (N = 257), the ORR was 73% and CR rate was 53%. The median (95% confidence interval) DOR, PFS, and OS were 23.1 (8.6 to not reached), 6.8 (3.3-12.7), and 27.3 months (16.2-45.6), respectively. Estimated 2-year DOR, PFS, and OS rates were 49.5%, 40.6%, and 50.5%, respectively. In the 90-day treatment-emergent period (N = 270), grade 3 to 4 cytokine release syndrome and neurological events occurred in 2% and 10% of patients, respectively. The most common grade ≥3 AEs in treatment-emergent and posttreatment-emergent periods, respectively, were neutropenia (60% and 7%) and anemia (37% and 6%). Liso-cel demonstrated durable remissions and a manageable safety profile with no new safety signals during the 2-year follow-up in patients with R/R LBCL. These trials were registered at www.ClinicalTrials.gov as #NCT02631044 and #NCT03435796.
引用
- Abramson JS, Palomba ML, Gordon LI, et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024. PMID: 37890149. doi:10.1182/blood.2023020854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。